Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that pubic skin fibroblasts respond to androgens, increasing 5α-reductase activity via an androgen receptor-mediated mechanism, suggesting its potential as a marker of androgen action in vitro.

This study identified LY191704 as a specific noncompetitive inhibitor of human 5 alpha-reductase type 1, which may be useful in treating endocrine disorders related to DHT overproduction.

This rat study suggests that 5α-dihydrotestosterone plays a critical role in inhibiting nipple development in male fetuses by causing the regression of the nipple anlage in utero.

Testosterone needs to be converted to DHT to reduce stress response in male rats.

This study found that spironolactone directly inhibits 5 alpha-reductase activity in hirsute women, resulting in decreased conversion of testosterone to dihydrotestosterone, which may contribute to its therapeutic effects.

This review discusses recent advancements in understanding the use of 5 alpha-reductase inhibitors for benign prostatic hyperplasia, indicating that dual isoenzyme inhibitors like dutasteride may enhance treatment outcomes, but no new clinical results are presented.

This study concludes that high skin 5α-reductase activity may contribute to hirsutism, but the specific regulatory mechanisms and genetic factors remain unclear.

This article reviews the role of 5α-reductase in cutaneous hyperandrogenism and the potential of 5α-reductase inhibitors and antiandrogens in treating conditions like hirsutism and male-pattern baldness, reporting no clinical results.

This review discusses the potential of 4-azasteroids as 5α-reductase inhibitors for treating hirsutism, reporting their promising effects in animal studies but noting no clinical trials have been conducted yet.

This study found that two new progesterone derivatives showed higher antiandrogenic effects and 5α-reductase inhibition than finasteride in hamsters, particularly reducing seminal vesicle weight and flank organ size.

This study found that three months of oral finasteride treatment significantly decreased dihydrotestosterone levels and hair growth in hirsute women without negatively affecting gonadotropin secretion.

A new method was developed to accurately measure enzyme activity related to prostate health.

This study found that young women with female-pattern hair loss exhibit increased testosterone production rates while dihydrotestosterone production rates remain within or below the normal range.

This study explored how modifying the 8-substituent of 8-bromobenzoquinolinone affects its selectivity in inhibiting both 5 alpha-reductase isozymes in the scalp.

This study found that components derived from Uromedic® pumpkin seeds, especially Δ7-sterols, may inhibit DHT production and AR binding, potentially benefiting prostate and bladder health by moderating these mechanisms.

In this study, 4-substituted N-(1,1-dimethylethyl)-3-oxo-4-androstene-17.beta.-carboxamides were synthesized and evaluated in vitro as potential 5 alpha-reductase inhibitors and antiandrogens.

This study reported that 5 alpha-reductase type 2 is the predominant enzyme in pubic skin fibroblasts across normal men, women, and hirsute patients, suggesting potential treatment options for idiopathic hirsutism.

Finasteride reduces testosterone conversion, progesterone lessens this, and levamisole enhances finasteride's effect.

This study in rats suggests that combining the 5 alpha-reductase inhibitor 4-MA with the antiandrogen Flutamide may enhance prostate cancer therapy by additively inhibiting prostatic growth and mRNA levels of androgen-sensitive prostatic binding proteins.

This study evaluated novel steroid compounds for their ability to inhibit 5α-reductase, showing that compound 16a significantly reduced rat prostate weight more than epristeride and exhibited excellent in vitro inhibitory potency, indicating its potential as a lead candidate for further benign prostatic hyperplasia drug research.

This study observed that a topical liposome formulation of a 5‐α‐reductase inhibitor effectively reduced the size of treated sebaceous glands and induced apoptosis in a hamster model, suggesting potential benefits for acne treatment.

The side gland of Suncus murinus is a good model for studying human sebaceous glands.

This theoretical study suggests that certain cannabinoid derivatives could potentially be effective as androgen receptor and 5α-reductase enzyme inhibitors, indicating they may be promising candidates for prostate cancer treatment based on their higher affinity to target proteins compared to standard drugs.

In this study, researchers developed a sensitive assay to measure the inhibition of steroid 5-α reductase (5AR) by chemicals like finasteride and dutasteride, revealing species-specific differences in inhibitor efficacy between human and fish cell lines.

This study found that among men with Benign Prostatic Hyperplasia, treatment with the 5α-reductase inhibitor finasteride for three months significantly reduced levels of dihydrotestosterone and estradiol, hormones involved in prostate enlargement, without altering follicle-stimulating hormone or luteinizing hormone levels.

This study designed a novel model for 5a-reductase enzyme inhibitors using pharmacophore and 3D QSAR techniques, potentially allowing for improved prediction and development of drug therapies targeting benign prostatic hyperplasia.

This study investigates the potential of onion extract as a treatment for androgenetic alopecia by using in silico and ADME/T analyses to examine how active compounds from onions interact with the 5-alpha-reductase enzyme.

In this study, researchers highlight the role of androgens like dihydrotestosterone in the pathophysiology of acne, pointing to the enzyme 5a-reductase type 1 as potentially more active in individuals with acne, which may contribute to hormonal influences in the condition's development.

This article presents a case of 5-alpha-reductase deficiency in a Saudi individual, reporting no new research findings.

This study reviewed recent scientific evidence on the neuroendocrine and metabolic impacts of chronic use of 5-alpha reductase inhibitors, detailing its association with sexual dysfunction, mood disorders, insulin resistance, and other metabolic disorders, suggesting persistent biopsycho-social risks beyond transient side effects in users.